HDAC6 and colorectal cancer: We previously described a novel HDAC6 selective inhibitor, C1A, that showed antitumor activity in a solid tumor model of human colorectal cancer.13 The molecular mechanisms by which tumors survive HDAC6 inhibitor treatment, however, remain unresolved.